Capricor Therapeutics, Inc.
September 30, 2024 - by Joey Ramson
$CAPR is leading the Prism MarketView Biotech index today and is looking to continue its large run-up from last week on news that the company said it will pursue full FDA approval for its drug Deramiocel.
